In short
Clinical trials are investigating HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1 in adults with idiopathic pulmonary fibrosis. These studies look at safety, tolerability, and whether the treatment can change disease activity. The main focus is on people with this lung disease in a Phase 2 trial.
Key points
- Clinical trials are studying HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1 in adults with idiopathic pulmonary fibrosis. The available trial is a Phase 2 interventional study with 165 participants. It is looking at safety, tolerability, and efficacy, meaning whether the treatment may help and how well people can take it. The main measured result is the change in forced vital capacity at Week 24. The trial is authorised and includes a placebo comparison.
Trial overview
The available study is an interventional trial, which means researchers give a study treatment and then measure what happens. It is testing HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1 in adults with idiopathic pulmonary fibrosis, also called IPF. The brief goal is to evaluate safety, tolerability, and efficacy, either as monotherapy or in combinations, in adult people with IPF.
Who can participate
This trial is for adult participants with idiopathic pulmonary fibrosis. The source data do not list more detailed entry rules, such as exact lung function limits or other medical requirements.
Study design and treatment groups
The study is a Phase 2 trial. Phase 2 studies are usually done after early testing and are used to see whether a treatment shows signs of benefit while continuing to watch safety. The treatment plan includes HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1 and a placebo for ABBV-142, which is a look-alike comparison treatment with no active study drug.
The trial title and summary show that the study is looking at adverse events and change in disease activity in adults with IPF. The study is also described as assessing the investigational products as monotherapy or in combinations.
What is being measured
The main outcome is the absolute change from baseline in forced vital capacity at Week 24. Forced vital capacity is the amount of air a person can blow out after taking the deepest breath possible, and baseline means the starting point before treatment begins. This outcome helps researchers see whether lung function changes over time during the study.
The study summary also says the researchers want to evaluate safety, tolerability, and efficacy. In simple terms, they want to know if the treatment can be given safely, whether people can handle it, and whether it may help the disease.
Trial status and size
The trial status is Authorised, which means it has official approval to proceed. The planned enrollment is 165 participants. This gives the study enough people to compare results and look for meaningful changes in lung function and disease activity.
Key terms for patients
Idiopathic pulmonary fibrosis is a lung disease that causes scarring, and the cause is not known. Adverse events are unwanted medical problems that happen during a study. Tolerability means how well people can handle the study treatment.
Efficacy means how well a treatment works for the condition being studied. Monotherapy means the treatment is given by itself, while combinations mean it may be studied with other treatments. Placebo is a comparison treatment that looks like the study drug but has no active study medicine.